Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Wei-Lin Jin,Ming-Zhu Jin,Yan-Yang Tu
DOI: https://doi.org/10.1016/j.trecan.2020.01.016
IF: 19.161
2020-01-01
Trends in Cancer
Abstract:Patient-derived organoids can recapitulate parental tumor heterogeneity. In a recent study in Cell, Jacob et al. cultivated glioblastoma organoids (GBOs) to mimic tumor heterogeneity and chimeric antigen receptor (CAR)-T cell immunotherapy, applied it for xenograft establishment and drug testing, and generated a biobank for the timely start of post-operation therapy.
What problem does this paper attempt to address?